4 Results for "

VCaP human prostate cancer cells

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "VCaP human prostate cancer cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-156111
CAS No.: 2632305-36-1
Purity:  99.36%
Research Areas:  

Neurological Disease Cancer

ARD-1676 is an orally active androgen receptor (AR) PROTAC degrader . ARD-1676 induces proteasomal degradation of AR, inhibits AR-regulated gene expression, suppresses cell growth, reduces AR protein levels and inhibits tumor growth in in vivo models. ARD-1676 can be used in studies related to AR+ human prostate cancer and spinal bulbar muscular atrophy .
loading...
    loading...
Cat. No.: HY-164807
CAS No.: 1489236-55-6
Target:  

HyT Androgen Receptor HSP

Research Areas:  

Cancer

SARD279 is a HyT degrader of androgen receptor (AR). SARD279 binds to AR, recruits HSP70, mediates ubiquitin-dependent proteasomal degradation, and competitively inhibits the transactivation of AR. SARD279 exhibits antiproliferative activity in AR-dependent prostate cancer cells and castration-resistant prostate cancer cells, including those harboring the AR F876L mutation. SARD279 can be used in studies related to prostate cancer and castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-148777
CAS No.: 2682255-44-1
Research Areas:  

Cancer

A031 is a PROTAC degrader targeting the androgen receptor. A031 induces time-dependent degradation of androgen receptor protein. A031 exerts tumor growth inhibitory effects in a zebrafish model xenografted with human prostate cancer cells. A031 can be used in studies related to prostate cancer .
loading...
    loading...
Cat. No.: HY-168201
CAS No.: 3105406-14-9
MJP6412 is a p300 and CBP PROTAC degrader that potently degrades p300 and CBP in 22Rv1 cells with DC50 values of 1.6 nM and 1.2 nM, respectively. MJP6412 downregulates the expression of AR-FL, AR-V7 and c-MYC, as well as androgen receptor target genes (KLK3, FKBP5, TMPRSS2). MJP6412 completely abolishes p300/CBP-dependent histone acetylation (H3K27Ac and H2BNTAC) and induces G1 cell cycle arrest. MJP6412 inhibits cancer cell proliferation and tumor growth. MJP6412 can be used in prostate cancer-related research .
loading...
    loading...